Q32 Bio Inc. (QTTB) 10-Year Financial Performance & Capital Metrics

QTTB • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutQ32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.Show more

Revenue $0 +100.0%
EBITDA -$66M -37.4%
Net Income -$48M +11.2%
EPS (Diluted) -6.58 +60.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -841.11%
ROIC -
Debt/Equity 3.33
Interest Coverage -220.34

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 94 (top 6%)
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗High debt to equity ratio of 3.3x
✗Weak Piotroski F-Score: 3/9
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM30.54%

EPS CAGR

10Y-

5Y-

3Y-

TTM55.86%

ROCE

10Y Avg-84.46%

5Y Avg-103.05%

3Y Avg-140.96%

Latest-121.49%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	5.32M	1.67M	2.7M	33.97M	6.65M	-6.65M	0
Revenue Growth %	-	-	-	-0.69%	0.62%	11.57%	-0.8%	-2%	1%
Cost of Goods Sold+	239.8K	684.21K	0	0	0	9.54M	0	0	487K
COGS % of Revenue	-	-	-	-	-	0.28%	-	-	-
Gross Profit+	-239.8K	-684.21K	5.32M	1.67M	2.7M	24.43M	6.65M	-6.65M	-487K
Gross Margin %	-	-	1%	1%	1%	0.72%	1%	1%	-
Gross Profit Growth %	-	-1.85%	8.78%	-0.69%	0.62%	8.04%	-0.73%	-2%	0.93%
Operating Expenses+	9.76M	28.97M	63.96M	105.29M	124.06M	120.38M	45.88M	41.6M	65.61M
OpEx % of Revenue	-	-	12.02%	63.2%	45.91%	3.54%	6.9%	-6.26%	-
Selling, General & Admin	4.07M	7.6M	16.01M	15.89M	23.67M	27.29M	10.06M	9.88M	17.47M
SG&A % of Revenue	-	-	3.01%	9.54%	8.76%	0.8%	1.51%	-1.48%	-
Research & Development	5.69M	21.38M	47.95M	89.4M	100.39M	93.08M	35.81M	31.73M	48.14M
R&D % of Revenue	-	-	9.01%	53.66%	37.15%	2.74%	5.38%	-4.77%	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0
Operating Income+	-10M	-29.66M	-59.93M	-109.94M	-130.26M	-95.95M	-39.23M	-48.26M	-66.1M
Operating Margin %	-	-	-11.26%	-65.99%	-48.21%	-2.82%	-5.9%	7.26%	-
Operating Income Growth %	-	-1.97%	-1.02%	-0.83%	-0.18%	0.26%	0.59%	-0.23%	-0.37%
EBITDA+	-9.76M	-28.97M	-58.64M	-103.63M	-121.36M	-86.41M	-38.85M	-47.76M	-65.61M
EBITDA Margin %	-	-	-11.02%	-62.2%	-44.91%	-2.54%	-5.84%	7.18%	-
EBITDA Growth %	-	-1.97%	-1.02%	-0.77%	-0.17%	0.29%	0.55%	-0.23%	-0.37%
D&A (Non-Cash Add-back)	239.8K	684.21K	1.29M	6.32M	8.9M	9.54M	370K	499K	487K
EBIT	-8.05M	-29.99M	-55.58M	-103.92M	-128.69M	-95.76M	-39.23M	-48.26M	-45.79M
Net Interest Income+	0	0	0	6.03M	1.57M	0	0	0	3.6M
Interest Income	24.2K	542.63K	4.35M	6.03M	1.57M	0	0	0	3.9M
Interest Expense	0	0	0	0	0	0	0	0	300K
Other Income/Expense	1.95M	-333.37K	4.35M	6.03M	1.57M	185K	-3.52M	-5.17M	18.39M
Pretax Income+	-8.05M	-29.99M	-55.58M	-103.92M	-128.69M	-95.76M	-42.75M	-53.42M	-47.71M
Pretax Margin %	-	-	-10.44%	-62.37%	-47.63%	-2.82%	-6.43%	8.03%	-
Income Tax+	2	-4	0	0	0	0	62K	318K	21K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1.01%	1%
Net Income+	-8.05M	-29.99M	-55.58M	-103.92M	-128.69M	-95.76M	-42.81M	-53.74M	-47.73M
Net Margin %	-	-	-10.44%	-62.37%	-47.63%	-2.82%	-6.44%	8.08%	-
Net Income Growth %	-	-2.73%	-0.85%	-0.87%	-0.24%	0.26%	0.55%	-0.26%	0.11%
Net Income (Continuing)	-8.05M	-29.99M	-55.58M	-103.92M	-128.69M	-95.76M	-42.81M	-53.74M	-47.73M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.87	-14.42	-35.04	-44.41	-50.46	-12.23	-13.42	-16.70	-6.58
EPS Growth %	-	-2.73%	-1.43%	-0.27%	-0.14%	0.76%	-0.1%	-0.24%	0.61%
EPS (Basic)	-3.87	-14.42	-35.04	-44.41	-50.46	-12.23	-13.42	-16.70	-5.12
Diluted Shares Outstanding	2.08M	2.08M	1.59M	2.34M	2.55M	3.07M	3.19M	3.22M	12.2M
Basic Shares Outstanding	2.08M	2.08M	1.59M	2.34M	2.55M	3.07M	3.19M	3.22M	12.2M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	11.99M	131.6M	221.69M	266.58M	219.56M	191.91M	46.85M	28.72M	81.88M
Cash & Short-Term Investments	11.39M	129.66M	214.74M	262.39M	217.43M	155.87M	43.89M	25.62M	77.97M
Cash Only	11.39M	51.57M	38.22M	53.77M	217.43M	108.38M	43.89M	25.62M	77.97M
Short-Term Investments	0	78.08M	176.52M	208.61M	0	47.49M	0	0	0
Accounts Receivable	113.26K	0	800K	400K	400K	0	1.06M	755K	555K
Days Sales Outstanding	-	-	54.87	87.64	54.03	-	58.39	-41.43	-
Inventory	0	0	0	0	0	0	1.75M	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	481.79K	1.94M	6.15M	3.79M	1.73M	36.04M	146K	83K	396K
Total Non-Current Assets+	2.23M	5.93M	37.41M	43.99M	44.17M	19.81M	14.92M	18.34M	10.46M
Property, Plant & Equipment	1.96M	3.15M	35.64M	42.72M	42.9M	17.86M	9.17M	8.08M	7.09M
Fixed Asset Turnover	-	-	0.15x	0.04x	0.06x	1.90x	0.73x	-0.82x	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	276K	1.77M	1.77M	1.27M	1.27M	1.95M	25.81M	0	2.6M
Other Non-Current Assets	0	1M	0	0	0	0	-20.06M	10.26M	763K
Total Assets+	14.22M	137.53M	259.09M	310.57M	263.74M	211.72M	61.77M	47.06M	92.33M
Asset Turnover	-	-	0.02x	0.01x	0.01x	0.16x	0.11x	-0.14x	-
Asset Growth %	-	8.67%	0.88%	0.2%	-0.15%	-0.2%	-0.71%	-0.24%	0.96%
Total Current Liabilities+	6.38M	8.86M	22.52M	12.37M	22.66M	17.23M	57.87M	14.11M	16.46M
Accounts Payable	893.67K	2.54M	15.73M	2.61M	4.72M	2.37M	1.44M	3.47M	2.99M
Days Payables Outstanding	1.36K	1.35K	-	-	-	90.49	-	-	2.24K
Short-Term Debt	0	0	0	0	2.5M	246K	32.4M	878K	3.1M
Deferred Revenue (Current)	0	1000K	770K	809K	1000K	1000K	1000K	0	0
Other Current Liabilities	5.48M	2.98M	6.02M	8.96M	9.8M	11.41M	2.79M	3M	5.68M
Current Ratio	1.88x	14.85x	9.84x	21.54x	9.69x	11.14x	0.81x	2.04x	4.97x
Quick Ratio	1.88x	14.85x	9.84x	21.54x	9.69x	11.14x	0.78x	2.04x	4.97x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	340.63K	30.36M	40.22M	39.69M	45.08M	24.84M	134.62M	215.87M	70.19M
Long-Term Debt	0	0	0	0	0	0	5.07M	43.18M	9.56M
Capital Lease Obligations	0	0	0	0	12.94M	23.69M	6.79M	6.25M	5.64M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	340.63K	290.92K	9.47M	9.54M	0	0	111.44M	166.44M	55M
Total Liabilities	6.72M	39.22M	62.74M	52.06M	67.74M	42.07M	192.49M	229.98M	86.66M
Total Debt+	0	0	0	0	15.44M	23.93M	44.73M	50.84M	18.9M
Net Debt	-11.39M	-51.57M	-38.22M	-53.77M	-201.99M	-84.45M	838K	25.22M	-59.06M
Debt / Equity	-	-	-	-	0.08x	0.14x	-	-	3.33x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-220.34x
Total Equity+	7.5M	98.31M	196.35M	258.51M	196M	169.65M	-130.71M	-182.92M	5.67M
Equity Growth %	-	12.11%	1%	0.32%	-0.24%	-0.13%	-1.77%	-0.4%	1.03%
Book Value per Share	3.61	47.28	123.79	110.48	76.84	55.24	-40.99	-56.83	0.47
Total Shareholders' Equity	7.5M	98.31M	196.35M	258.51M	196M	169.65M	-130.71M	-182.92M	5.67M
Common Stock	1.12K	1.39K	3K	4K	5K	6K	1K	1K	2K
Retained Earnings	-10.19M	-40.18M	-95.76M	-199.67M	-328.37M	-424.13M	-133.34M	-187.08M	-234.81M
Treasury Stock	0	0	0	0	0	0	715.93M	0	0
Accumulated OCI	-1.12K	-73.31K	-77K	183K	0	-7K	-404K	0	0
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.48M	6.48M	-42.56M	-91.36M	-94.33M	-109.75M	-10.96M	-18.68M	-67.72M
Operating CF Margin %	-	-	-8%	-54.84%	-34.91%	-3.23%	-1.65%	2.81%	-
Operating CF Growth %	-	1.76%	-7.57%	-1.15%	-0.03%	-0.16%	0.9%	-0.7%	-2.63%
Net Income	-8.05M	-29.99M	-55.58M	-103.92M	-128.69M	-95.76M	-42.81M	-53.74M	-47.73M
Depreciation & Amortization	239.8K	684.21K	1.29M	6.32M	8.9M	9.54M	370K	499K	487K
Stock-Based Compensation	0	0	0	0	0	0	1.24M	0	4.39M
Deferred Taxes	0	0	0	0	0	0	2.42M	0	0
Other Non-Cash Items	-1.64M	715.96K	-644K	5.78M	13.94M	18.27M	876K	8.25M	-15.22M
Working Capital Changes	928.48K	34.72M	10.56M	463K	11.52M	-41.8M	26.94M	26.32M	-9.64M
Change in Receivables	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0
Change in Payables	517.97K	1.72M	4.38M	-4.45M	2.46M	-2.49M	-1.24M	2.03M	-1.04M
Cash from Investing+	-2.27M	-81.53M	-121.79M	-51.8M	204.9M	-50.79M	-2.47M	-5K	19.93M
Capital Expenditures	-1.99M	-1.96M	-24.94M	-21.83M	-3.73M	-2.4M	-2.48M	-5K	-75K
CapEx % of Revenue	-	-	4.69%	13.11%	1.38%	0.07%	0.37%	-0%	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	-37.98M	0	0
Cash from Financing+	378.31K	115.23M	150.99M	158.21M	53.09M	52.17M	30.07M	406K	95.14M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	0	0	0	46.14M
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-10.47M	4.52M	-67.5M	-113.19M	-98.06M	-112.15M	-13.44M	-18.68M	-67.79M
FCF Margin %	-	-	-12.68%	-67.94%	-36.29%	-3.3%	-2.02%	2.81%	-
FCF Growth %	-	1.43%	-15.93%	-0.68%	0.13%	-0.14%	0.88%	-0.39%	-2.63%
FCF per Share	-5.04	2.17	-42.55	-48.37	-38.45	-36.51	-4.22	-5.80	-5.56
FCF Conversion (FCF/Net Income)	1.05x	-0.22x	0.77x	0.88x	0.73x	1.15x	0.26x	0.35x	1.42x
Interest Paid	0	0	0	0	0	0	0	0	856K
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-107.29%	-56.69%	-37.72%	-45.69%	-56.63%	-52.38%	-219.88%	-	-841.11%
Return on Invested Capital (ROIC)	-	-103.84%	-43.88%	-45.45%	-98.32%	-181.7%	-	-	-
Gross Margin	-	-	100%	100%	100%	71.91%	100%	100%	-
Net Margin	-	-	-1044.29%	-6237.45%	-4762.92%	-281.9%	-643.65%	808.04%	-
Debt / Equity	-	-	-	-	0.08x	0.14x	-	-	3.33x
Interest Coverage	-	-	-	-	-	-	-	-	-220.34x
FCF Conversion	1.05x	-0.22x	0.77x	0.88x	0.73x	1.15x	0.26x	0.35x	1.42x
Revenue Growth	-	-	-	-68.7%	62.18%	1157.25%	-80.42%	-200%	100%

Frequently Asked Questions

Growth & Financials

Q32 Bio Inc. (QTTB) grew revenue by 100.0% over the past year. This is strong growth.

Q32 Bio Inc. (QTTB) reported a net loss of $42.1M for fiscal year 2024.

Dividend & Returns

Q32 Bio Inc. (QTTB) has a return on equity (ROE) of -841.1%. Negative ROE indicates the company is unprofitable.

Q32 Bio Inc. (QTTB) had negative free cash flow of $38.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Q32 Bio Inc. (QTTB) 10-Year Financial Performance & Capital Metrics

QTTB • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $0 +100.0%
EBITDA -$66M -37.4%
Net Income -$48M +11.2%
EPS (Diluted) -6.58 +60.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -841.11%
ROIC -
Debt/Equity 3.33
Interest Coverage -220.34

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 94 (top 6%)
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗High debt to equity ratio of 3.3x
✗Weak Piotroski F-Score: 3/9
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM30.54%

EPS CAGR

10Y-

5Y-

3Y-

TTM55.86%

ROCE

10Y Avg-84.46%

5Y Avg-103.05%

3Y Avg-140.96%

Latest-121.49%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	5.32M	1.67M	2.7M	33.97M	6.65M	-6.65M	0
Revenue Growth %	-	-	-	-0.69%	0.62%	11.57%	-0.8%	-2%	1%
Cost of Goods Sold+	239.8K	684.21K	0	0	0	9.54M	0	0	487K
COGS % of Revenue	-	-	-	-	-	0.28%	-	-	-
Gross Profit+	-239.8K	-684.21K	5.32M	1.67M	2.7M	24.43M	6.65M	-6.65M	-487K
Gross Margin %	-	-	1%	1%	1%	0.72%	1%	1%	-
Gross Profit Growth %	-	-1.85%	8.78%	-0.69%	0.62%	8.04%	-0.73%	-2%	0.93%
Operating Expenses+	9.76M	28.97M	63.96M	105.29M	124.06M	120.38M	45.88M	41.6M	65.61M
OpEx % of Revenue	-	-	12.02%	63.2%	45.91%	3.54%	6.9%	-6.26%	-
Selling, General & Admin	4.07M	7.6M	16.01M	15.89M	23.67M	27.29M	10.06M	9.88M	17.47M
SG&A % of Revenue	-	-	3.01%	9.54%	8.76%	0.8%	1.51%	-1.48%	-
Research & Development	5.69M	21.38M	47.95M	89.4M	100.39M	93.08M	35.81M	31.73M	48.14M
R&D % of Revenue	-	-	9.01%	53.66%	37.15%	2.74%	5.38%	-4.77%	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0
Operating Income+	-10M	-29.66M	-59.93M	-109.94M	-130.26M	-95.95M	-39.23M	-48.26M	-66.1M
Operating Margin %	-	-	-11.26%	-65.99%	-48.21%	-2.82%	-5.9%	7.26%	-
Operating Income Growth %	-	-1.97%	-1.02%	-0.83%	-0.18%	0.26%	0.59%	-0.23%	-0.37%
EBITDA+	-9.76M	-28.97M	-58.64M	-103.63M	-121.36M	-86.41M	-38.85M	-47.76M	-65.61M
EBITDA Margin %	-	-	-11.02%	-62.2%	-44.91%	-2.54%	-5.84%	7.18%	-
EBITDA Growth %	-	-1.97%	-1.02%	-0.77%	-0.17%	0.29%	0.55%	-0.23%	-0.37%
D&A (Non-Cash Add-back)	239.8K	684.21K	1.29M	6.32M	8.9M	9.54M	370K	499K	487K
EBIT	-8.05M	-29.99M	-55.58M	-103.92M	-128.69M	-95.76M	-39.23M	-48.26M	-45.79M
Net Interest Income+	0	0	0	6.03M	1.57M	0	0	0	3.6M
Interest Income	24.2K	542.63K	4.35M	6.03M	1.57M	0	0	0	3.9M
Interest Expense	0	0	0	0	0	0	0	0	300K
Other Income/Expense	1.95M	-333.37K	4.35M	6.03M	1.57M	185K	-3.52M	-5.17M	18.39M
Pretax Income+	-8.05M	-29.99M	-55.58M	-103.92M	-128.69M	-95.76M	-42.75M	-53.42M	-47.71M
Pretax Margin %	-	-	-10.44%	-62.37%	-47.63%	-2.82%	-6.43%	8.03%	-
Income Tax+	2	-4	0	0	0	0	62K	318K	21K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1.01%	1%
Net Income+	-8.05M	-29.99M	-55.58M	-103.92M	-128.69M	-95.76M	-42.81M	-53.74M	-47.73M
Net Margin %	-	-	-10.44%	-62.37%	-47.63%	-2.82%	-6.44%	8.08%	-
Net Income Growth %	-	-2.73%	-0.85%	-0.87%	-0.24%	0.26%	0.55%	-0.26%	0.11%
Net Income (Continuing)	-8.05M	-29.99M	-55.58M	-103.92M	-128.69M	-95.76M	-42.81M	-53.74M	-47.73M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-3.87	-14.42	-35.04	-44.41	-50.46	-12.23	-13.42	-16.70	-6.58
EPS Growth %	-	-2.73%	-1.43%	-0.27%	-0.14%	0.76%	-0.1%	-0.24%	0.61%
EPS (Basic)	-3.87	-14.42	-35.04	-44.41	-50.46	-12.23	-13.42	-16.70	-5.12
Diluted Shares Outstanding	2.08M	2.08M	1.59M	2.34M	2.55M	3.07M	3.19M	3.22M	12.2M
Basic Shares Outstanding	2.08M	2.08M	1.59M	2.34M	2.55M	3.07M	3.19M	3.22M	12.2M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	11.99M	131.6M	221.69M	266.58M	219.56M	191.91M	46.85M	28.72M	81.88M
Cash & Short-Term Investments	11.39M	129.66M	214.74M	262.39M	217.43M	155.87M	43.89M	25.62M	77.97M
Cash Only	11.39M	51.57M	38.22M	53.77M	217.43M	108.38M	43.89M	25.62M	77.97M
Short-Term Investments	0	78.08M	176.52M	208.61M	0	47.49M	0	0	0
Accounts Receivable	113.26K	0	800K	400K	400K	0	1.06M	755K	555K
Days Sales Outstanding	-	-	54.87	87.64	54.03	-	58.39	-41.43	-
Inventory	0	0	0	0	0	0	1.75M	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	481.79K	1.94M	6.15M	3.79M	1.73M	36.04M	146K	83K	396K
Total Non-Current Assets+	2.23M	5.93M	37.41M	43.99M	44.17M	19.81M	14.92M	18.34M	10.46M
Property, Plant & Equipment	1.96M	3.15M	35.64M	42.72M	42.9M	17.86M	9.17M	8.08M	7.09M
Fixed Asset Turnover	-	-	0.15x	0.04x	0.06x	1.90x	0.73x	-0.82x	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	276K	1.77M	1.77M	1.27M	1.27M	1.95M	25.81M	0	2.6M
Other Non-Current Assets	0	1M	0	0	0	0	-20.06M	10.26M	763K
Total Assets+	14.22M	137.53M	259.09M	310.57M	263.74M	211.72M	61.77M	47.06M	92.33M
Asset Turnover	-	-	0.02x	0.01x	0.01x	0.16x	0.11x	-0.14x	-
Asset Growth %	-	8.67%	0.88%	0.2%	-0.15%	-0.2%	-0.71%	-0.24%	0.96%
Total Current Liabilities+	6.38M	8.86M	22.52M	12.37M	22.66M	17.23M	57.87M	14.11M	16.46M
Accounts Payable	893.67K	2.54M	15.73M	2.61M	4.72M	2.37M	1.44M	3.47M	2.99M
Days Payables Outstanding	1.36K	1.35K	-	-	-	90.49	-	-	2.24K
Short-Term Debt	0	0	0	0	2.5M	246K	32.4M	878K	3.1M
Deferred Revenue (Current)	0	1000K	770K	809K	1000K	1000K	1000K	0	0
Other Current Liabilities	5.48M	2.98M	6.02M	8.96M	9.8M	11.41M	2.79M	3M	5.68M
Current Ratio	1.88x	14.85x	9.84x	21.54x	9.69x	11.14x	0.81x	2.04x	4.97x
Quick Ratio	1.88x	14.85x	9.84x	21.54x	9.69x	11.14x	0.78x	2.04x	4.97x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	340.63K	30.36M	40.22M	39.69M	45.08M	24.84M	134.62M	215.87M	70.19M
Long-Term Debt	0	0	0	0	0	0	5.07M	43.18M	9.56M
Capital Lease Obligations	0	0	0	0	12.94M	23.69M	6.79M	6.25M	5.64M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	340.63K	290.92K	9.47M	9.54M	0	0	111.44M	166.44M	55M
Total Liabilities	6.72M	39.22M	62.74M	52.06M	67.74M	42.07M	192.49M	229.98M	86.66M
Total Debt+	0	0	0	0	15.44M	23.93M	44.73M	50.84M	18.9M
Net Debt	-11.39M	-51.57M	-38.22M	-53.77M	-201.99M	-84.45M	838K	25.22M	-59.06M
Debt / Equity	-	-	-	-	0.08x	0.14x	-	-	3.33x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-220.34x
Total Equity+	7.5M	98.31M	196.35M	258.51M	196M	169.65M	-130.71M	-182.92M	5.67M
Equity Growth %	-	12.11%	1%	0.32%	-0.24%	-0.13%	-1.77%	-0.4%	1.03%
Book Value per Share	3.61	47.28	123.79	110.48	76.84	55.24	-40.99	-56.83	0.47
Total Shareholders' Equity	7.5M	98.31M	196.35M	258.51M	196M	169.65M	-130.71M	-182.92M	5.67M
Common Stock	1.12K	1.39K	3K	4K	5K	6K	1K	1K	2K
Retained Earnings	-10.19M	-40.18M	-95.76M	-199.67M	-328.37M	-424.13M	-133.34M	-187.08M	-234.81M
Treasury Stock	0	0	0	0	0	0	715.93M	0	0
Accumulated OCI	-1.12K	-73.31K	-77K	183K	0	-7K	-404K	0	0
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.48M	6.48M	-42.56M	-91.36M	-94.33M	-109.75M	-10.96M	-18.68M	-67.72M
Operating CF Margin %	-	-	-8%	-54.84%	-34.91%	-3.23%	-1.65%	2.81%	-
Operating CF Growth %	-	1.76%	-7.57%	-1.15%	-0.03%	-0.16%	0.9%	-0.7%	-2.63%
Net Income	-8.05M	-29.99M	-55.58M	-103.92M	-128.69M	-95.76M	-42.81M	-53.74M	-47.73M
Depreciation & Amortization	239.8K	684.21K	1.29M	6.32M	8.9M	9.54M	370K	499K	487K
Stock-Based Compensation	0	0	0	0	0	0	1.24M	0	4.39M
Deferred Taxes	0	0	0	0	0	0	2.42M	0	0
Other Non-Cash Items	-1.64M	715.96K	-644K	5.78M	13.94M	18.27M	876K	8.25M	-15.22M
Working Capital Changes	928.48K	34.72M	10.56M	463K	11.52M	-41.8M	26.94M	26.32M	-9.64M
Change in Receivables	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0
Change in Payables	517.97K	1.72M	4.38M	-4.45M	2.46M	-2.49M	-1.24M	2.03M	-1.04M
Cash from Investing+	-2.27M	-81.53M	-121.79M	-51.8M	204.9M	-50.79M	-2.47M	-5K	19.93M
Capital Expenditures	-1.99M	-1.96M	-24.94M	-21.83M	-3.73M	-2.4M	-2.48M	-5K	-75K
CapEx % of Revenue	-	-	4.69%	13.11%	1.38%	0.07%	0.37%	-0%	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	-37.98M	0	0
Cash from Financing+	378.31K	115.23M	150.99M	158.21M	53.09M	52.17M	30.07M	406K	95.14M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	0	0	0	0	0	46.14M
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-10.47M	4.52M	-67.5M	-113.19M	-98.06M	-112.15M	-13.44M	-18.68M	-67.79M
FCF Margin %	-	-	-12.68%	-67.94%	-36.29%	-3.3%	-2.02%	2.81%	-
FCF Growth %	-	1.43%	-15.93%	-0.68%	0.13%	-0.14%	0.88%	-0.39%	-2.63%
FCF per Share	-5.04	2.17	-42.55	-48.37	-38.45	-36.51	-4.22	-5.80	-5.56
FCF Conversion (FCF/Net Income)	1.05x	-0.22x	0.77x	0.88x	0.73x	1.15x	0.26x	0.35x	1.42x
Interest Paid	0	0	0	0	0	0	0	0	856K
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-107.29%	-56.69%	-37.72%	-45.69%	-56.63%	-52.38%	-219.88%	-	-841.11%
Return on Invested Capital (ROIC)	-	-103.84%	-43.88%	-45.45%	-98.32%	-181.7%	-	-	-
Gross Margin	-	-	100%	100%	100%	71.91%	100%	100%	-
Net Margin	-	-	-1044.29%	-6237.45%	-4762.92%	-281.9%	-643.65%	808.04%	-
Debt / Equity	-	-	-	-	0.08x	0.14x	-	-	3.33x
Interest Coverage	-	-	-	-	-	-	-	-	-220.34x
FCF Conversion	1.05x	-0.22x	0.77x	0.88x	0.73x	1.15x	0.26x	0.35x	1.42x
Revenue Growth	-	-	-	-68.7%	62.18%	1157.25%	-80.42%	-200%	100%

Frequently Asked Questions

Growth & Financials

Q32 Bio Inc. (QTTB) grew revenue by 100.0% over the past year. This is strong growth.

Q32 Bio Inc. (QTTB) reported a net loss of $42.1M for fiscal year 2024.

Dividend & Returns

Q32 Bio Inc. (QTTB) has a return on equity (ROE) of -841.1%. Negative ROE indicates the company is unprofitable.

Q32 Bio Inc. (QTTB) had negative free cash flow of $38.8M in fiscal year 2024, likely due to heavy capital investments.